Skip to main content
SpringerLink
Log in

Association between transforming growth factor β1 polymorphisms and left ventricle hypertrophy in essential hypertensive subjects

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

Left ventricular hypertrophy (LVH) increases the risk of cardiovascular morbid events in hypertension. TGF-β1 is involved in pathologic states such as cardiac hypertrophy and cardiac fibrosis; we thus postulate that the TGF-β1 polymorphism is related to LVH in hypertensives. Six hundred and eighty essential hypertensive patients were recruited. Biochemical variables and clinical data were obtained and the determination of LVH was performed by echocardiography. According to the presence of LVH, all subjects were divided into the LVH+ and LVH− group. DNA was obtained, and two coding region polymorphisms of the TGF-β1 gene (+869 Leu→Proat codon 10 and +915 ARG→Pro at codon 25) were analyzed by the polymerase chain reaction. The product was cleaved with the restriction endonucleases. For the polymorphisms of the +869 Leu→Pro at codon 10, there was no marked difference in the distributions of genotypes and the allele frequencies between the LVH+ and LVH− subjects. For +915 Arg→Pro at codon 25, a significant difference in the distributions of genotypes of TGF-β1 was observed. The left ventricular mass index (LVMI) in Arg-Pro genotype carriers was significantly higher than those in the Arg-Arg and Pro-Pro carriers. Multivariate analysis showed that the Arg-Pro genotype was an independent risk factor for LVH (OR 3.23, 95% CI [1.48–5.63, P = 0.002]). The codon 10 genotypes did not show a significant association to LVH. Our data revealed a genetic association of TGF-β1+915 Arg→Pro at codon 25 polymorphism with LVH in a Chinese hypertensive population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Abbreviations

TGF-β1:

Transforming growth factor β1

LVH:

Left ventricular hypertrophy

LVMI:

Left ventricular mass index

References

  1. Koren MJ, Ulin RJ, Koren AT et al (2002) Left ventricular mass change during treatment and outcome in patients with essential hypertension. Am J Hypertens 15(12):1021–1028

    Article  PubMed  Google Scholar 

  2. Verdecchia P, Schillaci G, Borgioni C et al (1998) Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 97(1):48–54

    CAS  PubMed  Google Scholar 

  3. Verdecchia P, Porcellati C (1993) Defining normal ambulatory blood pressure in relation to target organ damage and prognosis. Am J Hypertens 6:207S–210S

    CAS  PubMed  Google Scholar 

  4. Levy D, Garrison RJ, Savage DD et al (1990) Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322:1561–1566

    CAS  PubMed  Google Scholar 

  5. Meijs MF, de Windt LJ, de Jonge N, Doevendans PA et al (2007) Left ventricular hypertrophy: a shift in paradigm. Curr Med Chem 14(2):157–171

    Google Scholar 

  6. Schmieder RE (2005) The role of non-haemodynamic factors of the genesis of LVH. Nephrol Dial Transplant 20(12):2610–2612

    Article  PubMed  Google Scholar 

  7. Arnett DK, de las Fuentes L, Broeckel U (2004) Genes for left ventricular hypertrophy. Curr Hypertens Rep 6(1):36–41

    Article  PubMed  Google Scholar 

  8. Deschepper CF, Boutin-Ganache I, Zahabi A et al (2000) In search of cardiovascular candidate genes: interactions between phenotypes and genotypes. Hypertension 39:332–336

    Article  Google Scholar 

  9. Ignotz RA, Massague J (1986) Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 261:4337–4345

    CAS  PubMed  Google Scholar 

  10. He ZY, Feng B, Yang SL et al (2005) Intracardiac basic fibroblast growth factor and transforming growth factor-beta 1 mRNA and their proteins expression level in patients with pressure or volume-overload right or left ventricular hypertrophy. Acta Cardiol 60:21–25

    Article  PubMed  Google Scholar 

  11. Agrotis A, Kalinina N, Bobik A (2005) Transforming growth factor-beta, cell signaling and cardiovascular disorders. Curr Vasc Pharmacol 3:55–61

    Article  CAS  PubMed  Google Scholar 

  12. Andreotti F, Porto I, Crea F, Maseri A (2002) Inflammatory gene polymorphisms and ischaemic heart disease: review of population association studies. Heart 87:107–112

    Article  CAS  PubMed  Google Scholar 

  13. Nikol S, Isner JM, Pickering JG et al (1992) Expression of transforming growth factor-beta 1 is increased in human vascular restenosis lesions. J Clin Invest 90:1582–1592

    Article  CAS  PubMed  Google Scholar 

  14. Lijnen PJ, Petrov VV, Fagard RH (2000) Induction of cardiac fibrosis by transforming growth factor-beta(1). Mol Genet Metab 71(1–2):418–435

    Article  CAS  PubMed  Google Scholar 

  15. Sie MP, Mattace-Raso FU, Uitterlinden AG et al (2007) TGF-beta1 polymorphisms and arterial stiffness; the Rotterdam Study. J Hum Hypertens 21(6):431–437

    CAS  PubMed  Google Scholar 

  16. Crobu F, Palumbo L, Franco E, et al (2008) Role of TGF-beta1 haplotypes in the occurrence of myocardial infarction in young Italian patients. BMC Med Genet 9:13

    Google Scholar 

  17. Sie MP, Uitterlinden AG, Bos MJ et al (2006) TGF-beta 1 polymorphisms and risk of myocardial infarction and stroke: the Rotterdam Study. Stroke 37(11):2667–2671

    Article  CAS  PubMed  Google Scholar 

  18. Koch W, Hoppmann P, Mueller JC et al (2006) Association of transforming growth factor-beta1 gene polymorphisms with myocardial infarction in patients with angiographically proven coronary heart disease. Arterioscler Thromb Vasc Biol 26(5):1114–1119

    Article  CAS  PubMed  Google Scholar 

  19. Cambien F, Ricard S, Troesch A et al (1996) Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure. The Etude Cas-Témoin de l’Infarctus du Myocarde (ECTIM) Study. Hypertension 28(5):881–887

    CAS  PubMed  Google Scholar 

  20. Xue H, Wang S, Wang H et al (2008) Atrial natriuretic peptide gene promoter polymorphism is associated with left ventricular hypertrophy in hypertension. Clin Sci 114(2):131–137

    Article  CAS  PubMed  Google Scholar 

  21. Rao M, Guo D, Jaber BL et al (2004) Transforming growth factor-beta 1 gene polymorphisms and cardiovascular disease in hemodialysis patients. Kidney Int 66(1):419–427

    Article  CAS  PubMed  Google Scholar 

  22. Holweg CT, Baan CC, Niesters HG et al (2001) TGF-beta1 gene polymorphisms in patients with end-stage heart failure. J Heart Lung Transplant 20(9):979–984

    Article  CAS  PubMed  Google Scholar 

  23. Holweg CT, Baan CC, Balk AH et al (2001) The transforming growth factor-beta1 codon 10 gene polymorphism and accelerated graft vascular disease after clinical heart transplantation. Transplantation 71(10):1463–1467

    Google Scholar 

  24. Yokota M, Ichihara S, Lin TL et al (2000) Association of a T29→C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 101(24):2783–2787

    CAS  PubMed  Google Scholar 

  25. Hallberg P, Karlsson J, Lind L et al (2004) Gender-specific association between preproendothelin-1 genotype and reduction of systolic blood pressure during antihypertensive treatment—results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). Clin Cardiol 27(5):287–290

    Article  CAS  PubMed  Google Scholar 

  26. Aziz TM, Hasleton PS, Yona N et al (2001) Transforming growth factor beta: association with arteriosclerosis and left ventricular dysfunction after heart transplantation. Transplant Proc 33:2334–2336

    Article  CAS  PubMed  Google Scholar 

  27. Awad MR, El-gamel A, Hasleton P et al (1998) Genotypic variation in the transforming growth factor-beta1 gene: Association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 66:1014–1020

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgment

This study is supported by a grant from health department of Zhejiang province (2006C068). The authors thank Dr. Han Yunfeng for his help in statistics.

Author information

Authors and Affiliations

  1. Department of Cardiology, Hangzhou First Municipal Hospital and Hangzhou Hospital, Nanjing Medical University, Huan-sha Road 261, Hangzhou, 310006, China

    Hai-Ying Xu, Xu-Wei Hou, Ning-Fu Wang & Jian Xu

  2. Department of Basic Medicine, Zhejiang Medical College, Hangzhou, 310053, China

    Li-Fang Wang

Authors
  1. Hai-Ying Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xu-Wei Hou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Li-Fang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ning-Fu Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jian Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xu-Wei Hou.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Xu, HY., Hou, XW., Wang, LF. et al. Association between transforming growth factor β1 polymorphisms and left ventricle hypertrophy in essential hypertensive subjects. Mol Cell Biochem 335, 13–17 (2010). https://doi.org/10.1007/s11010-009-0235-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11010-009-0235-x

Keywords

Search

Navigation